Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target increased by JMP Securities from $69.00 to $72.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. JMP Securities’ target price would indicate a potential upside of 177.14% from the stock’s current price.

Several other research analysts also recently commented on MIRM. SVB Leerink cut their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Monday. HC Wainwright lowered their price target on Mirum Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $37.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Finally, Raymond James lowered their price target on Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a report on Tuesday, December 19th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $52.11.

Mirum Pharmaceuticals Price Performance

NASDAQ MIRM traded down $0.79 during trading hours on Thursday, hitting $25.98. The company had a trading volume of 789,916 shares, compared to its average volume of 610,994. Mirum Pharmaceuticals has a 52 week low of $21.83 and a 52 week high of $35.56. The firm has a 50 day simple moving average of $27.59 and a 200 day simple moving average of $29.30. The company has a debt-to-equity ratio of 1.14, a quick ratio of 4.91 and a current ratio of 5.20. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -6.54 and a beta of 1.16.

Insider Buying and Selling

In related news, CFO Eric Bjerkholt purchased 2,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The shares were acquired at an average cost of $25.80 per share, for a total transaction of $51,600.00. Following the transaction, the chief financial officer now directly owns 12,000 shares in the company, valued at $309,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Eric Bjerkholt purchased 2,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 18th. The shares were acquired at an average cost of $25.80 per share, for a total transaction of $51,600.00. Following the transaction, the chief financial officer now directly owns 12,000 shares in the company, valued at $309,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Lara Longpre sold 1,019 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $28.04, for a total value of $28,572.76. Following the transaction, the insider now owns 105,254 shares in the company, valued at $2,951,322.16. The disclosure for this sale can be found here. Insiders have sold a total of 8,899 shares of company stock worth $248,102 in the last ninety days. 24.06% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its position in shares of Mirum Pharmaceuticals by 98.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after buying an additional 488 shares during the last quarter. AJOVista LLC bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $40,000. Wetzel Investment Advisors Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $41,000. Metropolitan Life Insurance Co NY grew its position in shares of Mirum Pharmaceuticals by 49.7% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,464 shares of the company’s stock worth $38,000 after buying an additional 486 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of Mirum Pharmaceuticals by 186.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,846 shares of the company’s stock worth $48,000 after buying an additional 1,202 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.